Verano Holdings Corp. (VRNOF)
(Delayed Data from OTC)
$3.84 USD
-0.06 (-1.54%)
Updated Aug 2, 2024 12:39 PM ET
4-Sell of 5 4
B Value B Growth B Momentum A VGM
Brokerage Reports
Verano Holdings Corp. [VRNOF]
Reports for Purchase
Showing records 121 - 140 ( 145 total )
Company: Verano Holdings Corp.
Industry: Medical - Products
2Q22 Mixed, Heavy Investment & NJ to Drive 2H22 Growth, Lower PT to $21
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: 2Q22 Cannabis Earnings - Week II Preview
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Cannabis Industry Update: 2Q22 Week II Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: MSO Uplisting Process, How SAFE Potentially Creates a Path
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Verano Holdings Corp.
Industry: Medical - Products
U.S. Cannabis 2Q22 Preview: Macro Impacting NT, Legislative Progess Warming
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Operating Income Gaining Investor Interest As Industry Matures
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
Signs of Recovery But Increasing Taxes Payable Pose a Challenge for H2/22
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Consumer Access Key - Opening More Retail Licenses
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Deferred Taxes, Another Low "Cost" Cash Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
1Q22 In-Line As Expected, Set Up to Drive Leading Margins, Reit Buy
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
NJ Adult-Use Cannabis Update: New Recreational Stores Added to Begin Sales
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Verano Holdings Corp.
Industry: Medical - Products
1Q22 Preview, NJ Investment/ Positioning to Drive Growth
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
4Q21 Messy with GAAP Transition, Still Best-in-Class, Lower PT to $26 - Buy
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
Q421 Results Show Larger than Expected Margin Blip Which will Persist into Q122, Upwards from Then, $240M Est. Operating Cashflow in 2022
Provider: Echelon Welath Partners
Analyst: SEMPLE A